IMO, these 2 big pharmacies will end up being interested in the chronic respiratory management of asthma and COPD when this product is available. I can't see a CR anytime soon given RAP has $8.5M (including the $1.5M from TK selling 10M shares at 15c) last quarter and also $1.5M R&D refund so around $10M cash available from last quarter.
Ann: AstraZeneca to use new ResApp software in clinical study, page-9
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
Add to My Watchlist
What is My Watchlist?